Invirsa
Latest round
- Series B
Last raised
- Dec 2022
Total raised
- $6.7M
Investors
- 4
About Invirsa
Invirsa, Inc. specializes in advancing therapeutic solutions for ocular conditions. Founded in 2016 by Robert Shalwitz, the company has undergone strategic developments to align its offerings with healthcare demands.819 mn.Invirsa’s primary product offering is its lead compound, INV-102, which enhances the body’s ability to respond to DNA damage. This innovative treatment is specifically designed to address ocular conditions resulting from DNA injury, including those caused by sulfur mustard gas exposure. INV-102 functions by stabilizing cellular structure at critical moments of DNA repair, thereby facilitating a more effective healing process. The compound targets conditions such as viral and bacterial conjunctivitis, which affect millions of individuals annually, particularly in the United States.S.6 mn collaboration with BARDA aimed at advancing the development of INV-102 for ocular conditions. This strategic partnership is indicative of the company’s approach to securing financial support while bringing its innovative product to market. Revenue generation may also involve B2B transactions with healthcare providers who will ultimately prescribe INV-102 to patients suffering from various ocular injuries.In November 2023, Invirsa, Inc. The company is committed to expanding its product line and addressing additional ocular health needs. Plans are in place to explore new geographic markets, particularly targeting regions with high incidences of ocular conditions, by 2024.
Who invested in Invirsa
4 investors across 3 rounds
See all investors in Invirsa
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Invirsa
Who invested in Invirsa?
Invirsa has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Invirsa raised?
Invirsa has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Invirsa last raise money?
Invirsa's most recent round on record is a Series B, in Dec 2022.
What does Invirsa do?
Invirsa is a biotechnology company.
Where is Invirsa headquartered?
Invirsa is headquartered in Columbus, US.
Which VCs invest in companies like Invirsa?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Invirsa's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Invirsa? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.